{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T13:50:19Z","timestamp":1774705819003,"version":"3.50.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Daptomycin's efficacy and toxicity are closely related to its exposure, which can vary widely among individuals. The patient, a 59-year-old male with an estimated glomerular filtration rate (eGFR) of 12 mL\/min\/1.73 m\u00b2 and a weight of 64 kg, was treated with 850 mg of daptomycin every other day for infective endocarditis caused by methicillin-resistant <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic> (MRSA). For patients with an estimated glomerular filtration rate of less than 30 mL\/min\/1.73 m\u00b2, the dosing recommendations are not explicitly defined in the endocarditis guidelines. Subsequently, the pharmacology department was contacted to adjust the dosage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A population pharmacokinetic model developed by Dvorchik et al. was used for Bayesian estimation of the patient\u2019s pharmacokinetic parameters. The 24-hour area under the curve (AUC24) of daptomycin was calculated at steady state using peak and trough plasma samples.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The minimum inhibitory concentration (MIC) of the MRSA strain was 0.25 mg\/L. An AUC24\/MIC ratio below 666 is associated with higher mortality risk, while an AUC24 above 939 h\u00b7mg\/L correlates with increased risk of muscular toxicity. Initial AUC24 estimation was 1091 h\u00b7mg\/L. Following a dosage reduction to 700 mg every other day, the AUC24 increased to 1600 h\u00b7mg\/L. Further reduction to 500 mg every other day brought the AUC24 down to 750 h mg\/L, with two subsequent measurements showing consistent AUC24 values of 500 h\u00b7mg\/L, which is within the target range.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Daptomycin ended 6 weeks after the initial negative blood culture, with no adverse effects or recurrence of MRSA infection. This case underscores the need for therapeutic drug monitoring and a multidisciplinary approach to adjust daptomycin doses in patients with renal impairment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001256","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T15:08:33Z","timestamp":1726153713000},"page":"695-698","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Daptomycin Dosage Optimization in Renal Impairment Using Model-Informed Precision Dosing"],"prefix":"10.1097","volume":"46","author":[{"given":"Hamza","family":"Sayadi","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeleen","family":"Fromage","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Labriffe","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France;"},{"name":"Pharmacology and Toxicology, Inserm, University of Limoges, CHU Limoges, UMR1248, Limoges, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Danthu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, CHU Limoges, Limoges, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Monchaud","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France;"},{"name":"Pharmacology and Toxicology, Inserm, University of Limoges, CHU Limoges, UMR1248, Limoges, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-0695","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France;"},{"name":"Pharmacology and Toxicology, Inserm, University of Limoges, CHU Limoges, UMR1248, Limoges, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM)","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"J Infect Chemother"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/cid\/ciad386","article-title":"Daptomycin exposure as a risk factor for daptomycin-induced eosinophilic pneumonia and muscular toxicity","volume":"77","author":"Garreau","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s40262-022-01168-5","article-title":"Daptomycin physiology-based pharmacokinetic modeling to predict drug exposure and pharmacodynamics in skin and bone tissues","volume":"61","author":"Garreau","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/psp4.12467","article-title":"Quantitative systems pharmacology and physiologically-based pharmacokinetic modeling with mrgsolve: a hands-on tutorial","volume":"8","author":"Elmokadem","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/psp4.12689","article-title":"Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr","volume":"10","author":"Le Louedec","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/FTD.0000000000000196","article-title":"Therapeutic drug monitoring of daptomycin: a retrospective monocentric analysis","volume":"37","author":"Reiber","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1128\/AAC.36.2.318","article-title":"Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers","volume":"36","author":"Woodworth","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.3390\/pharmaceutics14102226","article-title":"Population pharmacokinetic\/pharmacodynamic modelling of daptomycin for schedule optimization in patients with renal impairment","volume":"14","author":"Garc\u00eda-Mart\u00ednez","year":"2022","journal-title":"Pharmaceutics"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijantimicag.2018.09.015","article-title":"Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care institution","volume":"53","author":"Galar","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"923","DOI":"10.5414\/CP202538","article-title":"Staphylococcus aureus osteo-articular infection: usefulness of the determination of daptomycin serum concentration to explain a treatment failure","volume":"54","author":"Barreau","year":"2016","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:16:49Z","timestamp":1748971009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001256","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"2024-03-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}